EF-2001 EFFECT

Anti-Tumour Effect

Anti-tumour effect of EF-2001 in mice

Anti-tumour effect of EF-2001 on Meth-A fibrosarcom in mice

A suppression trend was observed in the EF-2001 group in contrast to the control group from around the 13th day following transplant, with a marked decrease in the size of the tumour from the 15th day.

Anti-tumour effect of EF-2001 on Sarcoma-180 in mice

The size of the tumour (mm2) in the EF-2001 group markedly decreased compared to the control group throughout the measurement period from the 2nd day of administration (the 4th day after tumour transplant), and a notable tumour growth inhibitory effect was observed.

Effectiveness in the treatment of atopy/allergy

Effectiveness in the treatment of atopic/allergic contact dermatitis

Mice, who developed atopic/allergic contact dermatitis by DNCB and ticks, were administered 2.25mg/kg of EF-2001 for four weeks (five times a week).

Mice started showing relief of symptom after a week, remarkable reduction of inflammation after 2 to 4 weeks, and the swelling on their ears were going down. The reduction of mast cells was recognized in the tissue examination.

The reduction of immunoglobin(IgE, IgG) was also recognized. Immunoglobin causes atopy.

It is recognized that the administration of EF-2001 has a therapeutic effect on atopic/allergic contact dermatitis.

Anti-Allergy Effect

Total IgE, IgG and IgM Measurements of EF-2001

Allergic reaction inhibition and immunity enhancing effect of EF-2001 by measuring total IgE, IgG and IgM

<Result: IgE Measurement>

 

Antibodies were produced in the EF-2001 group, with a decrease in total IgE concentration compared to the control group. This is thought to be because of an increase in the blood IL-2 level as a result of administering the EF-2001, with cytokine production in the spleen changing from Th2 to Th1.

Accordingly, IgG and IgE decreased, indicating an allergy-inhibitory effect.

Intestinal Flora Improvement Effect

Intestinal flora improvement effect of EF-2001 in humans

Change in intestinal flora by ingestion of EF-2001 in humans

Change in occupancy of intestinal flora by ingestion of EF-2001 in humans

Intestinal Flora Improvement Effect

Effect in Restoring Intestinal Flora

The effects of EF-2001 in restoring intestinal flora lost through the administration of antibiotics

Lactobacilli (beneficial bacteria) re-emerged earlier and in greater numbers in the EF-2001 group. Bifidobacteria (beneficial bacteria) also re-emerged in greater numbers. Conversely, Enterobacteriacae coliforms (harmful bacteria) re-emerged in lesser numbers. In other words, EF-2001 has a positive effect in restoring intestinal flora.

Comparison of Immunity-Specific Activity byBacteria Type

Comparison of TNF-α induction from macrophages by EF-2001 and other lactic acid bacteria

A comparison of the TNF-α induction potential of various lactic acid bacteria using macrophages collected from the oral cavities of mice indicated that EF-2001 scored the highest.

Radioprotective Effect

Immunity-boosting effect in mice that have ingested EF-2001 in a state of lowered resistance

Mice were administered EF-2001 for a two-week period. They were then exposed to radiation and the survival rate compared to that of the control group.

The EF-2001 group had a higher survival rate than the control group.

Immunity-Boosting Effect

Immunity-boosting effect in mice that have ingested EF-2001 in a state of lowered resistance

Mice were administered feed containing 10% EF-2001 for a two-week period. They were then administered immunosuppressant cyclophosphamide (CY) to put them into a state of lowered resistance, followed by an injection of E. coli from the tail vein. The number of bacteria in the liver was measured over time.

The EF-2001 group showed markedly fewer E. coli bacteria in the liver than the control group, indicating a non-specific immunity-boosting effect.

Intestinal Pathogen Preventative Effect

Intestinal pathogen (streptomycin-resistant E. coli) preventative effect in mice administered with EF-2001

Mice were administered feed containing 10% EF-2001 for a four-week period, then orally administered streptomycin-resistant (SM-resistant) exogenous E. coli bacteria. The number of SM-resistant E. coli bacteria in the excrement of the mice was measured.

SM-resistant E. coli quickly disappeared from the excrement, indicating an intestinal pathogen preventative effect.

Edema Inhibitory Effect

dema inhibitory effect on mice that have ingested EF-2001

Mice were administered EF-2001 for a two-week period. They were then subcutaneously injected with E. coli in the back, and after 10 days injected intracutaneously with the same E. coli on the sole of the foot and the edema measured. They were fed the test feed throughout the test period.

Edema from E. coli was more inhibited among mice in the EF-2001 group than in the control group.

Birth Defect Prevention Effect

Effect of prevention of birth defects due to radiation exposure in mice that have ingested EF-2001

Mice were divided into a group purely exposed to 2 Gy of radiation and a group exposed to 2 Gy of radiation following administration of EF-2001. The effect of EF-2001 on birth defects due to radiation exposure was examined.

Mice in the EF-2001 group showed a marked decrease in birth defect rate than the mice purely exposed to radiation.

Anti-Diabetic Effect

Effect of EF-2001 lactic acid bacteria on type II diabetes

EF-2001 was administered in single doses and serial doses of 250mg/kg to KK-Ay mice (mice with type II diabetes) and ddy mice (normal mice) and their glucose levels were measured.

A hypoglycaemic effect was observed in the KK-Ay mice (mice with type II diabetes) single dose group and serial dose group. No hypoglycaemic effect was observed in the normal mice groups.

Blood Pressure Elevation Inhibitory and Improved Liver Function Effects

Research Material

Blood pressure elevation inhibitory effect

Blood pressure elevation inhibitory effect in mice that have ingested EF-2001

Acute liver failure inhibitory effect

Suppressive effect of EF-2001 on acute liver failure in rats

Cancer Treatment Clinic

Hyperthermic cancer treatment enhancing effect

Effect of combined hyperthermic treatment and EF-2001 on cancer patients

Patients taking only hyperthermic treatment were compared to patients taking hyperthermic treatment together with an administration of EF-2001 lactic acid bacteria four times a day (1000mg/time).

As shown in the graphs, there is a marked difference between the hyperthermic-treatment-only patients and the EF-2001 patients in all tests, meaning that it is beneficial in treatment, particularly in terms of “reducing the treatment discontinuation rate” and “preventing white blood cell count phenomena”.

Hyperthermic treatment CT1

Oesophageal cancer

Pre-treatment

Post-treatment

Hyperthermic treatment CT2

Liver cancer

Pre-treatment

Post-treatment

Metastasis

Pre-treatment

Post-treatment

Hyperthermic treatment CT3

Lung cancer

Pre-treatment

Post-treatment

Orbital cancer

Pre-treatment

Post-treatment

Nasal cancer

Pre-treatment

Post-treatment

Radiotherapy Clinic

Effect of combined radiotherapy and EF-2001 on cancer patients

Effect of combined radiotherapy and EF-2001 on cancer patients

The QOL of patients taking only radiotherapy was compared to that of patients taking radiotherapy together with an administration of EF-2001 lactic acid bacteria four times a day (1000mg/time).

Patients taking only radiotherapy

Patients taking radiotherapy together with an administration of EF-2001 lactic acid bacteria four times a day (100mg/time)

As shown in the graphs, there is a marked difference between the radiotherapy-only patients and the EF-2001 patients in all tests, meaning that it is beneficial in radiotherapy.

Radiotherapy CT1

CASE

Pre-treatment

Post-treatment

Radiotherapy CT2

CASE

Pre-treatment

Post-treatment

Radiotherapy CT3

CASE

Pre-treatment

Post-treatment

CASE

Pre-treatment

Post-treatment

Radiotherapy CT4

CASE

Pre-treatment

Post-treatment

CASE

Pre-treatment

Post-treatment

Radiotherapy CT5

CASE

Pre-treatment

Post-treatment

2018 all rights reserved by H&J Inc.